Revvity, a leading provider of health science solutions, has introduced Revvity Transcribe AI, an advanced optical character recognition (OCR) service designed to digitize handwritten test request forms. The service aims to address the challenges of manual data entry in clinical laboratories, a process often fraught with inefficiencies and prone to errors. With its AI-supported technology, Revvity Transcribe AI can process forms with 40% faster workflow speeds, including data validation, enabling laboratories to redeploy personnel to other critical tasks. This service holds particular value for newborn screening (NBS) laboratories, seamlessly integrating with Revvity's EVOYA NBS software to digitize data from dried blood spot (DBS) test cards processed daily in public screening labs.
Revvity, a member of the S&P 500 index, reported over $2.7 billion in revenue in 2023 and serves customers across more than 190 countries. Specializing in health science innovations, the company focuses on areas such as translational multi-omics, biomarker identification, and diagnostics. With over 11,000 employees, Revvity aims to revolutionize healthcare through its integrated solutions. According to Norm Lord, Vice President of Digital Products at Revvity, the new OCR service not only enhances data accuracy and security but also integrates seamlessly with laboratory management systems, allowing clinical teams to prioritize time-sensitive tasks.
